Reason #1: Psilocybin Treats Depression and Other Illnesses Better
Than Any Other Pharmaceuticals Currently Available in Clinical Trials

Psilocybin is the substance derived from mushrooms and studies show it treats an amazingly wide range of psychiatric and neurological conditions better than current medications, including:

• Depression
• Anxiety
• PTSD (Post Traumatic Stress Disorder)
• Alcohol and drug addiction
• Alzheimer’s disease
• ADHD
• Traumatic brain injury
• Neuropathic pain
• End-of-life angst

And that’s where Mindset Pharma (OTC: MSSTF / CSE: MSET) enters the picture and not only offers 704 million people a new, better chance at relief from depression, anxiety and other mental ailments, but also investors the chance at potentially eye-popping profits.

Reason #2: Mindset Pharma creates a better psilocybin

Despite its efficacy, psilocybin has drawbacks, which Mindset has overcome. For one, psilocybin is a somewhat “messy” drug. It breaks down into a number of different compounds in the body, only one of which (psilocin) has therapeutic value.

The “byproduct” compounds provide no benefit to the patient and create the possibility of toxic side effects. In fact, patients who take other prescription drugs as well as psilocybin are almost guaranteed to experience side effects since these byproduct compounds tend to interact with other medications.

Mindset has overcome the purity problem by developing a patent-pending process for creating a synthetic psilocybin in the laboratory that has all the benefits of the compound extracted from mushrooms, but without any of the side effects.

Mindset isn’t the first company to produce a synthetic psilocybin. However, it has a synthesis process that gives it a huge competitive advantage.

Reason #3: Mindset makes psilocybin affordable

According to Matthew Johnson, a professor at John Hopkins University who has conducted extensive research, pharmaceutical grade psilocybin costs between $7,000 and $10,000 per gram.

The conventional approach is so expensive because the people doing the work, the chemistry procedures used to synthesize the compound, the purity of pre-cursors, and the equipment used in the manufacturing process all have to meet exacting FDA standards. Mindset has cleverly devised a way to combine some of the steps in this extremely complicated process.

The company’s patent-pending methodology still complies with FDA regulations, but radically reduces production costs. And it’s scalable, meaning it can be used to produce psilocybin in commercial quantities without losing the cost advantage. During a recent conversation, Joseph Araujo, Mindset’s Chief Scientific Officer, told us that this new approach allows the company to produce psilocybin for “hundreds, not thousands of dollars.” Even at $1,000, Mindset’s cost would be just 10% to 14.2% of what it costs competitors to produce psilocybin. And slashing the cost of a key drug component by 90% is usually a sure path to outsized profits.

This means it could sell its products for less than other companies and could thus grab more market share faster. However valuable this synthesis process is, what the company is doing with it could turn out to be even more valuable.

Reason #4: Multiple ways to profit

Mindset is using its patent-pending synthesis process to create not just one drug candidate, but over 75 different psilocybin based compounds, divided into two different groups:

The Macro dosing compounds are designed to work quickly, but to wear off quickly as well. This type of drug must be administered in a medical facility.

The Micro dosing compounds are designed to be taken regularly in small doses. The lower dosage provides therapeutic results without causing a hallucinogenic experience, which is one of the reasons psychedelic drugs got such a bad rep for a while. Because these drugs have a longer duration, they benefit the patient throughout the day. Micro dosing is the preferred approach for treating, for example, ADHD in children where a hallucinogenic experience is undesirable.

The company’s psilocybin-based compounds have undergone successful in vitro and in vivo testing. And selected candidates are now ready for the next step on the road to eventual FDA approval.

In addition to its psilocybin-based compounds, Mindset is researching drugs based on DMT and 5-MeO-DMT. These naturally occurring chemicals found in many plants have a chemical structure similar to tryptamine, a close cousin of dopamine
and serotonin.

 Reason #5: Everything that makes a small-cap biotech stock so profitable

In addition to promising research (and more to come), Mindset Pharma has all of the things we look for in a small-cap biotech stock:

• Patent-protected intellectual property (over 75 psilocybin-based drug candidates, plus an additional amounts based on DMT and 5-MeO-DMT)
• A huge potential market (704 million people!)
• Sufficient cash to fund research ($8.5 million to fund development)
• Solid management and an extremely talented science team
• A competitive edge (a synthesis process that slashes costs 90%)

Our new Special Report, Mindset Pharma and The Psychotropic Drug Revolution, is a good place to start your own due diligence research. It’s one of  4 Special Reports (a combined $99 value) you’ll receive with a no-risk trial subscription to Streetlight Equity’s online newsletter.

Each issue of Streetlight Equity newsletter brings you:

• In-depth fundamental and technical analysis of our favorite stock that month and how to position yourself for maximum profit. In our feature article each month, you’ll get the whole story behind the company. What they do, what’s their competitive advantage in the industry, why they’re positioned to see big growth and the steps you need to take next to profit.
• Our forecast for the economy, the political climate, and their impact on the markets. If you ignore these important factors, you’re leaving money on the table.
• Long term investment ideas to create a powerful and profitable foundation for your portfolio. We identified marijuana as an investment opportunity back in 2014 when it was just a budding industry… we see similar opportunities in the psilocybin market today.
• Short term stock ideas that can bring you even quicker profits if you’re a more aggressive investor.

Save 60% and receive 4 FREE Special Reports

A six month subscription to Streetlight Equity newsletter is just $39 — a 60% discount off the regular price. Plus, if you subscribe for a full year today at $74, you’ll also receive up to four FREE Special Reports valued at $79.20.

• FREE Special Report #1: Mindset Pharma and The Psychotropic Drug Revolution (a $19.80 value)
• FREE Special Report #2: 3 Stocks Potentially Set to Skyrocket to 300% or More (a $19.80 value)
• FREE Special Report #3: 4 Steps to Trade Like a Pro (a $19.80 value)

And if you respond within 10 days, you’ll receive an extra FREE Special Report:

• FREE Special Report #4: 2 Little Known Microcap Stocks Poised to Explode in 2021 (a $19.80 value )

Your trial subscription is risk-free because you’re fully protected by…